219 related articles for article (PubMed ID: 35358652)
21. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptors signature reveal the head and neck squamous cell carcinoma energy metabolism phenotype and clinical outcome.
Yao Y; Wang D; Zhang Y; Tang Q; Xu Z; Qin L; Qu Y; Yan Z
J Gene Med; 2024 Jan; 26(1):e3605. PubMed ID: 37932968
[TBL] [Abstract][Full Text] [Related]
23. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
Gong X; Ren F
Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
[TBL] [Abstract][Full Text] [Related]
24.
Dai Y; Chen W; Huang J; Cui T
Biomed Res Int; 2021; 2021():8874578. PubMed ID: 34285919
[TBL] [Abstract][Full Text] [Related]
25. NUTF2 as a Prognostic Indicator and Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Li P; Wen X; Zhang X; Wang F; Zhang D; Shang H
Genet Test Mol Biomarkers; 2022 Dec; 26(12):553-563. PubMed ID: 36577127
[No Abstract] [Full Text] [Related]
26. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
27. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
Hu Y; Chen J; Liu M; Feng Q; Peng H
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
[TBL] [Abstract][Full Text] [Related]
28. Relationship of biglycan and decorin expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma.
Liu M; Wang W; Piao S; Shen Y; Li Z; Ding W; Li J; Saiyin W
J Oral Pathol Med; 2023 Jan; 52(1):20-28. PubMed ID: 36308714
[TBL] [Abstract][Full Text] [Related]
29. Integrative Bioinformatics Analysis Identifies NEK2 as a Potential Biomarker in Head and Neck Squamous Cell Carcinoma.
Liu S; Tian W; Li B
J Comput Biol; 2020 Jan; 27(1):100-108. PubMed ID: 31460782
[TBL] [Abstract][Full Text] [Related]
30. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
31. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
32. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma.
Zhang Y; Chen K; Li L; Mao W; Shen D; Yao N; Zhang L
Ann Transl Med; 2021 Sep; 9(18):1443. PubMed ID: 34733995
[TBL] [Abstract][Full Text] [Related]
33. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
34. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
35. CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway.
Jia W; Chen S; Wei R; Yang X; Zhang M; Qian Y; Liu H; Lei D
Sci Rep; 2023 Jul; 13(1):10956. PubMed ID: 37414830
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
Zhang F; Liu Y; Yang Y; Yang K
BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
[TBL] [Abstract][Full Text] [Related]
37. Biomarker Potential of
Ju Y; Zhu F; Fang B
Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
[TBL] [Abstract][Full Text] [Related]
38. Expression and prognostic potential of PLEK2 in head and neck squamous cell carcinoma based on bioinformatics analysis.
Wang J; Sun Z; Wang J; Tian Q; Huang R; Wang H; Wang X; Han F
Cancer Med; 2021 Sep; 10(18):6515-6533. PubMed ID: 34331382
[TBL] [Abstract][Full Text] [Related]
39. Prognostic biomarker GSTK1 in head and neck squamous cell carcinoma and its correlation with immune infiltration and DNA methylation.
Feng Y; Zhou YH; Zhao J; Su XL; Chen NX; Zhao YQ; Ye Q; Hu J; Ou-Yang ZY; Zhong MM; Yang YF; Han PJ; Guo Y; Feng YZ
Front Genet; 2023; 14():1041042. PubMed ID: 36936420
[No Abstract] [Full Text] [Related]
40. The prognostic value of faciogenital dysplasias as biomarkers in head and neck squamous cell carcinoma.
Ma C; Li H; Li X; Lu S; He J
Biomark Med; 2019 Nov; 13(16):1399-1415. PubMed ID: 31596126
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
